Meeting
2021 ASCO Quality Care Symposium
Treatment initiation with bone-targeting agents among patients with bone metastasis secondary to solid tumors or patients with multiple myeloma.
Authors
Oth Tran
IBM Watson Health, San Francisco, CA
Oth Tran, Mark Hatfield, Meghan Moynihan, Neel Shah, Laurie A. Costa, Hossam Saad, Nicolas Despiegel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Patient Experience; Quality, Safety, and Implementation Science; Technology and Innovation in Quality of Care
Track
Technology and Innovation in Quality of Care,Patient Experience,Quality, Safety, and Implementation Science,Cost, Value, and Policy,Health Care Access, Equity, and Disparities
Sub Track
Real-World Evidence
Citation
J Clin Oncol 39, 2021 (suppl 28; abstr 309)
DOI
10.1200/JCO.2020.39.28_suppl.309
Abstract #
309
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Quality Care Symposium
Real-world variability in use of bone-modifying drugs for multiple myeloma by payer type.
First Author: SOPHIA Monica Monica Soni
Poster
2022 ASCO Genitourinary Cancers Symposium
Use of bone modifying agents for metastatic castrate-resistant prostate cancer.
First Author: Aaron Philip Mitchell
Poster
2021 ASCO Annual Meeting
Risk factors associated with skeletal-related events following denosumab cessation among patients with bone metastases from solid tumors: A real-world machine learning approach.
First Author: Alison Stopeck
Poster
2018 Palliative and Supportive Care in Oncology Symposium
Incidence of skeletal-related events in men with castration-resistant prostate cancer.
First Author: Alison Tse Kawai